Solvonis Therapeutics plc (LON:SVNS)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.2440
-0.0160 (-6.15%)
Sep 9, 2025, 4:35 PM BST
-6.15%
Market Cap16.65M
Revenue (ttm)n/a
Net Income (ttm)-1.59M
Shares Out6.40B
EPS (ttm)-0.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume40,812,376
Average Volume74,876,375
Open0.2540
Previous Close0.2600
Day's Range0.2440 - 0.2690
52-Week Range0.1100 - 0.3900
Beta1.52
RSI38.04
Earnings DateSep 12, 2025

About Solvonis Therapeutics

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product candidate includes SVN-SDN-14 for the treatment of post-traumatic stress disorder. The company was formerly known as Graft Polymer... [Read more]

Founded 2017
Employees 3
Stock Exchange London Stock Exchange
Ticker Symbol SVNS
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.